239095-84-2 Usage
General Description
2,3-dibromo-6,7-dichloro-1,2,3,4-tetrahydroquinoxaline is a chemical compound with the molecular formula C8H6Br2Cl2N. It is a type of quinoxaline derivative and consists of two bromine atoms, two chlorine atoms, and a tetrahydroquinoxaline ring structure. 2,3-dibromo-6,7-dichloro-1,2,3,4-tetrahydroquinoxaline is used in organic synthesis and drug development due to its potential pharmacological properties. It has been studied for its potential use in pharmaceuticals, including as a central nervous system depressant and for its antimicrobial activity. Under specific conditions and in controlled environments, 2,3-dibromo-6,7-dichloro-1,2,3,4-tetrahydroquinoxaline shows promising potential for various applications in medicinal and pharmaceutical chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 239095-84-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,3,9,0,9 and 5 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 239095-84:
(8*2)+(7*3)+(6*9)+(5*0)+(4*9)+(3*5)+(2*8)+(1*4)=162
162 % 10 = 2
So 239095-84-2 is a valid CAS Registry Number.
InChI:InChI=1/C8H6Br2Cl2N2/c9-7-8(10)14-6-2-4(12)3(11)1-5(6)13-7/h1-2,7-8,13-14H
239095-84-2Relevant articles and documents
Synthesis and structure-activity relationship of 2-amino-3-heteroaryl-quinoxalines as non-peptide, small-molecule antagonists for interleukin-8 receptor
Li, Jie Jack,Carson, Kenneth G.,Trivedi, Bharat K.,Yue, Wen Song,Ye, Qing,Glynn, Roberta A.,Miller, Steven R.,Connor, David T.,Roth, Bruce D.,Luly, Jay R.,Low, Joseph E.,Heilig, David J.,Yang, Weixing,Qin, Shixin,Hunt, Stephen
, p. 3777 - 3790 (2007/10/03)
Interleukin-8 modulation is implicated in many inflammatory and cancer diseases. Starting from a mass-screening hit, the synthesis and structure-activity relationship of 2-amino-3-heteroarylquinoxalines as non-peptide, small molecule interleukine-8 receptor antagonists have been developed. The optimized derivatives, PD 0210293 (13y) and PD 0220245 (13r), show inhibition of both IL-8 receptor binding and IL-8-mediated neutrophil chemotaxis.